| pubmed-article:19255727 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C0243192 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C0011209 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C1336636 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C1883254 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C0014020 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C1704419 | lld:lifeskim |
| pubmed-article:19255727 | lifeskim:mentions | umls-concept:C0289787 | lld:lifeskim |
| pubmed-article:19255727 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:19255727 | pubmed:dateCreated | 2009-5-6 | lld:pubmed |
| pubmed-article:19255727 | pubmed:abstractText | The effectiveness of vaccines depends on the age and immunocompetence of the vaccinee. Conventional non-adjuvanted influenza vaccines are suboptimal in the elderly and vaccines with improved ability to prevent influenza are required. The TLR4 agonist E6020, either given alone or co-delivered with MF59, was evaluated and compared to MF59 and the TLR9 agonist CpG. Its ability to enhance antibody titres and to modulate the quality of the immune response to a subunit influenza vaccine was investigated. | lld:pubmed |
| pubmed-article:19255727 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19255727 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19255727 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19255727 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19255727 | pubmed:issn | 1573-904X | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:WackAndreasA | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:HawkinsLynn... | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:SinghManmohan... | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:KazzazJinaJ | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:O'HaganDerek... | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:RonconiVaness... | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:BaudnerBarbar... | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:TortoliMarcoM | lld:pubmed |
| pubmed-article:19255727 | pubmed:author | pubmed-author:CasiniDaniele... | lld:pubmed |
| pubmed-article:19255727 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19255727 | pubmed:volume | 26 | lld:pubmed |
| pubmed-article:19255727 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19255727 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19255727 | pubmed:pagination | 1477-85 | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:meshHeading | pubmed-meshheading:19255727... | lld:pubmed |
| pubmed-article:19255727 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19255727 | pubmed:articleTitle | MF59 emulsion is an effective delivery system for a synthetic TLR4 agonist (E6020). | lld:pubmed |
| pubmed-article:19255727 | pubmed:affiliation | Novartis Vaccines, Via Fiorentina 1, Siena, Italy. barbara.baudner@novartis.com | lld:pubmed |
| pubmed-article:19255727 | pubmed:publicationType | Journal Article | lld:pubmed |
